

The ALIGN Study is testing an investigational medication called atrasentan that has the potential to reduce the amount of protein in urine and preserve kidney function in patients with IgA nephropathy. The study will begin enrolling patients in late 2020.

TARGETED THERAPY for IgA Nephropathy

You may qualify to participate in the ALIGN study if you:

- Are 18 years of age or older
- Have been diagnosed with IgA nephropathy from a kidney biopsy
- Are taking a stable dose of an ACE inhibitor or ARB for at least 12 weeks or are unable to tolerate ACEi/ARB treatment

Study participation



The study team will monitor your health through on-site clinic visits, remote visits (comprised of telemedicine and home health visits), and/or telephone calls.

For more information or to see if you may qualify, visit AlignStudy.com or contact:



Clinical Trial Reference Number:

